Report: Assembling the pharmaceutical R&D puzzle for needs in the developing world.
Pugatch Consilium – Meir Perez Pugatch, Rachel Chu & David Torstensson
New report offers a blueprint to boost research and development (R&D) for diseases of the developing world
The IFPMA announced a new study was released “reviewing initiatives to encourage research and development (R&D) for diseases such as HIV, tuberculosis, malaria and neglected tropical diseases.” The report introduces “a blueprint based on six enabling factors that comprise: identification of gaps in the R&D process, mitigation of risk and cost of R&D, ability to translate research into clinical outcomes, sustainability of funding for specific disease areas, effective access to new medicines, and compatibility with different R&D mechanisms.” The report also provides a review of key mechanisms currently being discussed by global health policymakers which “delink the cost of R&D from the price of medicines, such as open databases, research grants, and advanced market commitments.” The report’s authors conclude that multiple mechanisms are required to effectively address diverse R&D needs of the developing world. http://www.ifpma.org/fileadmin/content/News/2012/FINAL_-__IFPMA_Press_Release_-_R_D_in_developing_world_study_-_10_May_2012.pdf